Drug
AK 104
AK 104: highest development phase Phase 1, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK-104 NCT03261011 | Phase 1 | Advanced Cancer |
Latest
No recent events.
Follow AK 104 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.